U.S. Patent No. 10,137,161 B2 (‘161) issued on November 27, 2018, for “Medical Cannabis Lozenges and Compositions Thereof.” It was issued to applicant/inventor Jeffrey A. Kolsky of San Francisco, California. Kolsky is the owner of JollyMeds, which makes cannabis-infused edibles.
The ‘161 claims are directed to a composition in the form of a lozenge, consisting essentially of extractions of C. sativa and C. indica oils and xylitol. Further limitations include lozenge composition of a minimum of 25 mg of CBD, and a maximum of 40 mg of THC. Additional ‘161 claims are directed to various methods for preparing the lozenge composition, and methods for minimization of THC’s psychoactive elements when administered through a sublingual.
The following figure illustrates the disclosed invention of the ‘161 patent.
Source: U.S. Patent No. 10,137,161, Nov. 27, 2018, to Jeffrey A. Kolsky (applicant/inventor)
The International Patent Classifications are A61K (preparations for medical, dental purposes, namely medical preparations characterized by special physical form, containing organic active ingredients, or undetermined constitution, e.g., traditional herbal medicines).
This is example of a new inventions focused on medical treatments derived from various cannabis compounds. The ‘161 patent is focused on edibles, namely lozenge for medical use. Therapeutic uses and methods of uses are popular inventions dealing with cannabis that many companies are seeking patent protection. However, there are many other cannabis-edible innovations that could qualify for patent protection.
Please contact Yonaxis for more information on any of the IP processes described in this posting if you have any questions.